Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 2/20 | 0.43 |
| ▸ | CTSD | P07339 | 1/20 | 0.43 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | KAT7 | O95251 | 2/20 | 0.40 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.40 |
| ▸ | FPR3 | P25089 | 1/20 | 0.40 |
| ▸ | FPR2 | P25090 | 1/20 | 0.40 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.40 |
| ▸ | FEN1 | P39748 | 1/20 | 0.40 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.39 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29269441 | 0.89 | GPR119 (0.47) | GPR119CYP2C9BACE1CTSDCHEK2 | |
| SCHEMBL29269366 | 0.84 | GPR119 (0.53) | GPR119CYP2C9BACE1CTSDCHEK2 | |
| SCHEMBL31270116 | 0.84 | MEN1 (0.46) | GPR119CYP2C9BACE1CTSDCHEK2 | |
| SCHEMBL31270183 | 0.84 | SCN9A (0.43) | CYP2C9BACE1CTSDCHEK2SCN9A | |
| SCHEMBL29269340 | 0.84 | SCN9A (0.43) | CYP2C9BACE1CTSDCHEK2SCN9A | |
| SCHEMBL31270437 | 0.83 | GPR119 (0.46) | GPR119CYP2C9BACE1CTSDCHEK2 | |
| SCHEMBL31269794 | 0.83 | GPR119 (0.51) | GPR119CHEK2SCN9A | |
| SCHEMBL29269431 | 0.81 | ALDH1A1 (0.39) | — | |
| SCHEMBL31270293 | 0.80 | HTR6 (0.47) | GPR119CYP2C9BACE1CTSDCHEK2 | |
| SCHEMBL31270108 | 0.79 | CHEK2 (0.53) | GPR119CYP2C9BACE1CTSDCHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4301736-B1 | MACROCYCLIC COMPOUNDS AS PROTEASOME SUBUNIT BETA TYPE-5 INHIBITORS | LEAD DISCOVERY CENTER GMBH (DE) | 2025-10-08 | — | — | EP | disclosed |
| US-20240415819-A1 | MACROCYCLIC COMPOUNDS AS PROTEASOME SUBUNIT BETA TYPE-5 INHIBITORS | QLi5 Therapeutics AG (DE) | 2024-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240415819-A1 | MACROCYCLIC COMPOUNDS AS PROTEASOME SUBUNIT BETA TYPE-5 INHIBITORS | PSMB5, PSMA5, PSMB1 | GPR119 4139/4885CYP2C9 2797/4885BACE1 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.